Tyrosine kinase inhibitors induce mesenchymal stem cell–mediated resistance in BCR-ABL(+) acute lymphoblastic leukemia

Tyrosine kinase inhibitors (TKIs) are used as a frontline therapy for BCR-ABL(+) acute lymphoblastic leukemia (ALL). However, resistance to TKI therapy arises rapidly, and its underlying molecular mechanisms are poorly understood. In this study, we identified a novel cascade of events initiated by T...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Mallampati, Saradhi, Leng, Xiaohong, Ma, Haiqing, Zeng, Jianfang, Li, June, Wang, Haiying, Lin, Kevin, Lu, Yue, Yang, Yang, Sun, Baohua, Gong, Yun, Lee, Ju-Seog, Konopleva, Marina, Andreeff, Michael, Arlinghaus, Ralph B., Cai, Zhen, Fang, Bingliang, Shen, Haifa, Han, Xin, Hirsch-Ginsberg, Cheryl F., Gao, Xiaolian, Paranjape, Anurag N., Mani, Sendurai A., Clise-Dwyer, Karen, Sun, Xiaoping
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2015
Pynciau:
Lymphoid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424418/
https://ncbi.nlm.nih.gov/pubmed/25712988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-576421
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg